What this treatment is and who it is for

For many patients with cartilage damage, the answer to the most immediate question — can this be treated without an operation? — is yes.

ChondroFiller injection is an ultrasound-guided outpatient procedure that places an injectable collagen scaffold directly onto the cartilage defect. The entire appointment takes place in a clinic room: no general anaesthetic, no surgical incision, and no operating theatre. Real-time imaging is used throughout, allowing the clinician to navigate the needle to the exact site of damage and confirm scaffold deposition before the needle is withdrawn. Accurate placement at the cartilage surface is integral to how the treatment works — the scaffold must coat the defect to function as intended.

The treatment is applicable across a wide range of joints, including the knee, hip, ankle, shoulder, elbow, wrist, thumb, and temporomandibular joint. There is no upper age limit, and the injection route carries no defect-size cap. Patients with focal cartilage damage, early-to-moderate osteoarthritis, or post-traumatic cartilage loss across any of these joints may be candidates, subject to clinical assessment.

In the UK, ChondroFiller injection is delivered at the London Cartilage Clinic on Harley Street.

Why ultrasound guidance is necessary, not optional

The reason imaging cannot be skipped comes down to what the scaffold is supposed to do.

ChondroFiller liquid works by coating the load-bearing cartilage surface — the precise site of the defect — rather than simply entering the joint capsule. Reaching that surface accurately requires the operator to visualise needle-tip position in real time, relative to the cartilage, and to confirm scaffold deposition before withdrawing. Without that confirmation, there is no reliable way to know the material has arrived at its intended location.

The orthobiologics literature provides useful independent context here. Studies across anatomical sites show that up to 30% of injections performed using anatomical landmarks alone miss the intended intralesional target, the result of natural variation in joint anatomy between individuals. That figure reflects general injection practice rather than ChondroFiller specifically, but it illustrates the core problem: placing a scaffold whose function depends entirely on surface contact demands a tighter margin of accuracy than a diffuse therapeutic agent.

In the current outpatient injection pathway, real-time ultrasound is the standard imaging modality. Fluoroscopic guidance is an alternative where clinically indicated. Both allow continuous visualisation throughout the procedure and give the operator the ability to adjust needle position before scaffold release, then verify that the material has conformed to the cartilage surface as intended.

For context: some manufacturer documentation and historical clinical literature describes ChondroFiller delivery arthroscopically into a dry, surgically prepared joint. That is a distinct route and a distinct clinical setting — not the current outpatient injection pathway.

What the collagen scaffold does once it is in place

The moment ChondroFiller liquid contacts the fluid environment of the joint, it begins to polymerise — transitioning from a flowable liquid into a hydrogel that conforms to the contours of the cartilage defect. This in-situ gelation requires no external heat, catalyst, or mechanical compression; the chemistry of the joint environment drives the transition. The result is an immediate physical layer at the cartilage surface: a collagen scaffold sitting directly over the worn area, providing a mechanical cushion between the damaged tissue and the load passing through the joint.

This is where the additive character of the treatment becomes meaningful. Rather than cutting tissue away and exposing the subchondral bone before rebuilding can begin — the underlying logic of surgical debridement-and-reconstruct approaches — ChondroFiller injection layers a protective scaffold onto what is already there. An accessible way to picture it: paint applied over a worn surface rather than stripping back to bare wood before recoating.

The scaffold introduces no cells from outside. ChondroFiller is acellular — composed entirely of murine-derived Type I collagen, with no cellular component added during manufacture. Over the following six to twelve months, the patient's own progenitor cells, drawn from the synovium and subchondral bone, migrate into the collagen matrix. There they populate the scaffold, lay down new extracellular matrix, and progressively remodel the structure toward cartilage-like tissue. This process — the recruitment and differentiation of the patient's own cells by a cell-free scaffold — is described clinically as acellular matrix-induced chondrogenesis. The biology of repair is the patient's own; the scaffold simply provides the architecture for it to take place.

The appointment from first image to walking out

On the day itself, the appointment follows a clear sequence. It opens with a review of any prior imaging — MRI or X-ray — alongside real-time ultrasound assessment of the affected joint. This defect-mapping stage allows the treating clinician to confirm the precise location and extent of the cartilage lesion before any preparation begins.

Local anaesthesia is then administered to the joint area. Most patients report feeling mild pressure during the injection rather than sharp discomfort; the local anaesthetic is in place before the needle advances toward the cartilage surface. For patients who prefer additional reassurance, mild sedation is available, though general anaesthesia is neither required nor used.

Intravenous antibiotic cover is routinely given at this stage as a precautionary measure. At London Cartilage Clinic, Professor Paul Y. F. Lee then performs the ultrasound-guided injection: the needle is advanced under continuous imaging, positioned at the cartilage defect, and the ChondroFiller liquid is released to coat the target surface. The injection step itself takes only a few minutes once preparation is complete.

Brief post-procedure checks follow to confirm the patient is comfortable and that there are no immediate concerns. The appointment ends the same day — no overnight stay is needed. Before leaving, the patient will have a six-week follow-up appointment arranged, giving them a defined next step from the moment they walk out.

Clinical outcomes at one year and what the evidence covers

At one year, clinical data from the manufacturer's Clinical Evaluation Report (CER v09, April 2025) show IKDC scores improving by approximately 30 points in knee cases — a shift that moves many patients from the moderate-to-severe symptom band into the mild-to-moderate range. Pain scores on the NRS and DASH questionnaires fall markedly over the same period, and objective measures of function — grip strength and pincer strength — improve significantly alongside them.

Post-treatment MRI adds a structural dimension to those functional scores. Scans confirm reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space. These findings reflect a biological process underway in the joint rather than evidence that full cartilage restoration has occurred; the scaffold and the cells it recruits are progressively remodelling the joint environment, and MRI captures that shift.

The safety record is similarly consistent. The CER records a serious complication rate of approximately 0% and a reoperation rate of 3–8%. That figure merits brief context: a small proportion of patients go on to a further intervention — whether a top-up injection or a surgical procedure — and this rate aligns with the natural history of cartilage pathology in this population rather than pointing to a systematic problem with the treatment.

One note on interpreting these results: the evidence base to date is primarily drawn from the manufacturer's clinical evaluation programme; independent long-term studies on the outpatient injection route specifically are not yet available in the published literature. Findings are consistent across reported cohorts, and the structural MRI data lend them corroboration — though what outcomes look like beyond the one-year mark remains a question the field has yet to fully answer.

Costs, eligibility, and how to access the treatment in London

Guide costs at London Cartilage Clinic start at £3,000 for a single box of ChondroFiller liquid (2.3 mL) — the volume sufficient for most single focal defects. Larger surface areas or multi-compartment joints may require two or three boxes, bringing the guide cost to £5,500 and £8,000 respectively. Those figures cover consultation, real-time ultrasound, the product itself, the injection, intravenous antibiotic cover, and the six-week follow-up appointment. All pricing should be confirmed with the clinic before booking.

As noted earlier, the injection route carries no upper age limit and no defect-size restriction, making it applicable across a broad range of patients and joints.

Keeping the scaffold environment in good condition over the longer term involves a two-yearly top-up injection. The collagen matrix can be refreshed at this interval, extending its protective and regenerative function across the joint surface. Most patients also follow a programme of yearly peptide support and annual MRI monitoring to track the joint's response over time.

ChondroFiller injection in the UK is delivered at London Cartilage Clinic on Harley Street — the UK certified delivery centre for the treatment. Assessment appointments can be booked at londoncartilage.com.